July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Estela Rodriguez: FDA Oncology Approves Taletrectinib for ROS1+ mNSCLC
Jun 13, 2025, 10:11

Estela Rodriguez: FDA Oncology Approves Taletrectinib for ROS1+ mNSCLC

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:

“FDA Oncology approves taletrectinib (IBTROZI) for ROS1+ mNSCLC
High Response rates, high CNS activity (IC-ORR 76.5%)
  • TKI naive: ORR: 85-90% (TRUST-I – II) DOR ≥12 mo: 72%
  • TKI-pretreated: ORR: 52% -62% (TRUST-I-II) DOR ≥6 mo: 74%
  • low neuro side effects
  • TRAEs: liver tox, pneumonitis, QTc, hyperuricemia, myalgia.”

Estela Rodriguez: FDA Oncology Approves Taletrectinib for ROS1+ mNSCLC

Title: Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST

Authors: Maurice Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu, Yuichiro Ohe, Filippo De Braud, Misako Nagasaka, Enriqueta Felip, Anwen Xiong, Yongchang Zhang, Huijie Fan, Xicheng Wang, Shuanglian Li, Rose K. Lai, Feiwu Ran, Xianyu Zhang, Wenfeng Chen, Lyudmila Bazhenova, Caicun Zhou.

Estela Rodriguez: FDA Oncology Approves Taletrectinib for ROS1+ mNSCLC

You can read the Full Article in the Journal of Clinical Oncology.

More posts featuring Estela Rodriguez.